Logo image of BTMD

BIOTE CORP -A (BTMD) Stock Fundamental Analysis

NASDAQ:BTMD - Nasdaq - US0906831039 - Common Stock - Currency: USD

2.88  -0.04 (-1.37%)

Fundamental Rating

6

BTMD gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. BTMD has an average financial health and profitability rating. BTMD is valued quite cheap, while showing a decent growth score. This is a good combination! With these ratings, BTMD could be worth investigating further for value investing!.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year BTMD was profitable.
In the past year BTMD had a positive cash flow from operations.
BTMD had positive earnings in 4 of the past 5 years.
BTMD had a positive operating cash flow in 4 of the past 5 years.
BTMD Yearly Net Income VS EBIT VS OCF VS FCFBTMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M -60M

1.2 Ratios

BTMD has a Return On Assets of 13.68%. This is amongst the best in the industry. BTMD outperforms 95.88% of its industry peers.
Looking at the Return On Invested Capital, with a value of 43.56%, BTMD belongs to the top of the industry, outperforming 99.48% of the companies in the same industry.
Industry RankSector Rank
ROA 13.68%
ROE N/A
ROIC 43.56%
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BTMD Yearly ROA, ROE, ROICBTMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 400 600

1.3 Margins

The Profit Margin of BTMD (6.85%) is better than 85.57% of its industry peers.
In the last couple of years the Profit Margin of BTMD has declined.
Looking at the Operating Margin, with a value of 16.78%, BTMD belongs to the top of the industry, outperforming 86.08% of the companies in the same industry.
In the last couple of years the Operating Margin of BTMD has declined.
The Gross Margin of BTMD (71.27%) is better than 79.38% of its industry peers.
BTMD's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 16.78%
PM (TTM) 6.85%
GM 71.27%
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
BTMD Yearly Profit, Operating, Gross MarginsBTMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so BTMD is creating value.
Compared to 1 year ago, BTMD has less shares outstanding
The debt/assets ratio for BTMD is higher compared to a year ago.
BTMD Yearly Shares OutstandingBTMD Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
BTMD Yearly Total Debt VS Total AssetsBTMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

An Altman-Z score of 2.75 indicates that BTMD is not a great score, but indicates only limited risk for bankruptcy at the moment.
BTMD has a Altman-Z score of 2.75. This is in the better half of the industry: BTMD outperforms 72.16% of its industry peers.
BTMD has a debt to FCF ratio of 4.81. This is a neutral value as BTMD would need 4.81 years to pay back of all of its debts.
BTMD's Debt to FCF ratio of 4.81 is amongst the best of the industry. BTMD outperforms 84.54% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 4.81
Altman-Z 2.75
ROIC/WACC4.51
WACC9.65%
BTMD Yearly LT Debt VS Equity VS FCFBTMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

A Current Ratio of 1.42 indicates that BTMD should not have too much problems paying its short term obligations.
The Current ratio of BTMD (1.42) is worse than 69.59% of its industry peers.
BTMD has a Quick Ratio of 1.14. This is a normal value and indicates that BTMD is financially healthy and should not expect problems in meeting its short term obligations.
BTMD has a Quick ratio of 1.14. This is in the lower half of the industry: BTMD underperforms 71.65% of its industry peers.
Industry RankSector Rank
Current Ratio 1.42
Quick Ratio 1.14
BTMD Yearly Current Assets VS Current LiabilitesBTMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

6

3. Growth

3.1 Past

BTMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 328.57%, which is quite impressive.
BTMD shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -48.53% yearly.
The Revenue has been growing slightly by 6.38% in the past year.
BTMD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.38% yearly.
EPS 1Y (TTM)328.57%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%166.67%
Revenue 1Y (TTM)6.38%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%-0.63%

3.2 Future

BTMD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 48.92% yearly.
Based on estimates for the next years, BTMD will show a quite strong growth in Revenue. The Revenue will grow by 9.89% on average per year.
EPS Next Y182.82%
EPS Next 2Y49.7%
EPS Next 3Y49.45%
EPS Next 5Y48.92%
Revenue Next Year3.12%
Revenue Next 2Y5.82%
Revenue Next 3Y8.84%
Revenue Next 5Y9.89%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
BTMD Yearly Revenue VS EstimatesBTMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
BTMD Yearly EPS VS EstimatesBTMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 1 1.5

More info and screens

10

4. Valuation

4.1 Price/Earnings Ratio

BTMD is valuated cheaply with a Price/Earnings ratio of 3.20.
Based on the Price/Earnings ratio, BTMD is valued cheaply inside the industry as 97.42% of the companies are valued more expensively.
BTMD's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.48.
BTMD is valuated cheaply with a Price/Forward Earnings ratio of 5.84.
93.81% of the companies in the same industry are more expensive than BTMD, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 34.04. BTMD is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 3.2
Fwd PE 5.84
BTMD Price Earnings VS Forward Price EarningsBTMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, BTMD is valued cheaper than 94.33% of the companies in the same industry.
BTMD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BTMD is cheaper than 98.45% of the companies in the same industry.
Industry RankSector Rank
P/FCF 3.98
EV/EBITDA 6.23
BTMD Per share dataBTMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BTMD has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as BTMD's earnings are expected to grow with 49.45% in the coming years.
PEG (NY)0.02
PEG (5Y)N/A
EPS Next 2Y49.7%
EPS Next 3Y49.45%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BTMD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOTE CORP -A

NASDAQ:BTMD (8/8/2025, 8:21:52 PM)

2.88

-0.04 (-1.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-10 2025-11-10/amc
Inst Owners66.02%
Inst Owner Change-3.91%
Ins Owners9.81%
Ins Owner Change8.21%
Market Cap145.76M
Analysts83.33
Price Target6.8 (136.11%)
Short Float %3.04%
Short Ratio7.34
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)228.05%
Min EPS beat(2)-1.96%
Max EPS beat(2)458.07%
EPS beat(4)2
Avg EPS beat(4)111.48%
Min EPS beat(4)-269.68%
Max EPS beat(4)458.07%
EPS beat(8)4
Avg EPS beat(8)19.41%
EPS beat(12)6
Avg EPS beat(12)-81.15%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.5%
Min Revenue beat(2)-4.66%
Max Revenue beat(2)1.66%
Revenue beat(4)1
Avg Revenue beat(4)-1.68%
Min Revenue beat(4)-4.66%
Max Revenue beat(4)1.66%
Revenue beat(8)3
Avg Revenue beat(8)-1.48%
Revenue beat(12)5
Avg Revenue beat(12)-1.05%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-10.74%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-23.24%
EPS NY rev (1m)0%
EPS NY rev (3m)52.5%
Revenue NQ rev (1m)0.05%
Revenue NQ rev (3m)-2.41%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.06%
Valuation
Industry RankSector Rank
PE 3.2
Fwd PE 5.84
P/S 0.59
P/FCF 3.98
P/OCF 3.29
P/B N/A
P/tB N/A
EV/EBITDA 6.23
EPS(TTM)0.9
EY31.25%
EPS(NY)0.49
Fwd EY17.12%
FCF(TTM)0.72
FCFY25.1%
OCF(TTM)0.88
OCFY30.42%
SpS4.86
BVpS-1.78
TBVpS-2.07
PEG (NY)0.02
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 13.68%
ROE N/A
ROCE 55.13%
ROIC 43.56%
ROICexc 98.25%
ROICexgc 177.09%
OM 16.78%
PM (TTM) 6.85%
GM 71.27%
FCFM 14.86%
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-32.05%
ROICexcg growth 5YN/A
ROICexc growth 3Y-33.38%
ROICexc growth 5YN/A
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
F-Score6
Asset Turnover2
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 4.81
Debt/EBITDA 3.22
Cap/Depr 210.54%
Cap/Sales 3.15%
Interest Coverage 4.43
Cash Conversion 98.57%
Profit Quality 216.82%
Current Ratio 1.42
Quick Ratio 1.14
Altman-Z 2.75
F-Score6
WACC9.65%
ROIC/WACC4.51
Cap/Depr(3y)122.96%
Cap/Depr(5y)152.59%
Cap/Sales(3y)2.04%
Cap/Sales(5y)2.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)328.57%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%166.67%
EPS Next Y182.82%
EPS Next 2Y49.7%
EPS Next 3Y49.45%
EPS Next 5Y48.92%
Revenue 1Y (TTM)6.38%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%-0.63%
Revenue Next Year3.12%
Revenue Next 2Y5.82%
Revenue Next 3Y8.84%
Revenue Next 5Y9.89%
EBIT growth 1Y32.35%
EBIT growth 3Y-2.97%
EBIT growth 5Y6.11%
EBIT Next Year53.39%
EBIT Next 3Y25.44%
EBIT Next 5Y19.2%
FCF growth 1Y849.75%
FCF growth 3Y8.58%
FCF growth 5Y10.09%
OCF growth 1Y1512.04%
OCF growth 3Y10.29%
OCF growth 5Y12.28%